Alimta Indications/Uses

Malignant Pleural Mesothelioma: Treatment of chemotherapy-naive patients with unresectable malignant pleural mesothelioma, in combination with cisplatin.
Non-Small Cell Lung Cancer: First-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see Pharmacology: Pharmacodynamics under Actions), in combination with cisplatin.
As a monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. First-line treatment should be a platinum based with other cytotoxics chemotherapy (see Pharmacology: Pharmacodynamics under Actions).
As a single-agent for the treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer after prior chemotherapy (as second line).
Alimta is not indicated for treatment of patients with squamous cell non-small cell lung cancer.